SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its recent growth and upcoming utilities like staking and a mobile app. With a focus on community and consistent development, traders are closely watching the project's progress toward the next token burn milestone. Bullish sentiment remains high as the community celebrates new watchers and anticipates airdrop details.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending due to its status as the first Bitcoin-native meme coin, launched via the Runes protocol, generating community excitement around its unique position. The airdrop of $DOG tokens to Runestone holders has fueled discussions about fair distribution and the potential for organic growth within the Bitcoin ecosystem. Community members highlight its strong engagement and potential for listings on major exchanges.

Forward Industries, Inc. engages in the provision of integrated design, development, and manufacturing solutions for top tier medical and technology customers worldwide. It operates through the following segments: OEM Distribution, Retail Distribution, and Design. The OEM Distribution segment sources and distributes carrying cases and other accessories for medical monitoring and diagnostic kits and a variety of other portable electronic and non-electronic devices. The Retail Distribution segment sells smart-enabled furniture and a variety of other products through agreements with various retailers, both in stores and through online retailer websites. The Design segment provides hardware and software product design and engineering services. The company was founded in 1961 and is headquartered in Hauppauge, NY.

Forward Industries, Inc.

Forward Industries ($FORD) is trending due to a significant after-hours surge, with community members speculating about potential catalysts, compliance news and comparing it to similar low-float runners like $AREB. Some traders are mistaking it for Ford Motor Company ($F), contributing to the heightened interest, while others highlight its low float and potential for a short squeeze.

Brewski

$BREWSKI.X is trending as the community highlights unusual whale activity and anticipates it being the next big runner. The token is being touted as a symbol of American spirit and brotherhood, with community members encouraging others to grab a 'cold, hard earned' Brewski. Conversations also mention potential links to other meme tokens and the broader crypto market.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

VOLT ($XVM.X) is trending as the community discusses its potential as a real-world asset (RWA) token. Conversations revolve around its recent launch, ease of access via Phantom wallets, and speculation about significant market cap growth. Some users are drawing comparisons to other RWA coins like $XRP.X and $XLM.X.

Merging the worlds of decentralized computation and gaming to scale compute while you have a blast!  $GMRX: A token for our entire economy and our fully-built, plug-and-play cloud computing, games distribution and gamer experiences platform.  Decentralized computation:  1. Targeting the 1.6 billion desktop gamers globally.  2. Biggest active decentralized GPU sharing network.  3. Automatic GPU monetization (AI, Render & Mining Jobs).  Gaming:  1. We own Gaimin Gladiators, one of the top esports organizations in the world.  2. Integrated web2 and web3 gaming platform with NFT functionality and in-app marketplace.

Gaimin

Gaimin ($GMRX.X) is trending amid community excitement, with some users highlighting the platform's growing user base and potential utility. Discussion centers on the upcoming release of 'PRO' features and potential buybacks. The project is described as an AI, DePIN, and gaming token.

A memecoin.  Memecoin is exactly what it sounds like—a memecoin called memecoin. In a world dominated by meme-driven hype and community spirit, it only makes sense to have a token that embodies the entire memecoin movement. Launched on PEPE’s birthday, memecoin aims to represent the absurdity, humor, and heart of the memecoin economy. It’s here to bring hope, laughter, and a bit of chaos—while never pretending to be more than it is: just a memecoin. And maybe that’s exactly what we need.

Memecoin

Memecoin is trending as social media buzz focuses on potential gains in the broader meme coin sector, particularly around related token $GASH.X. Community members are speculating about potential for quick returns and comparing it to previous hyped coins, while also sharing links to Telegram groups.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to news of a land sale boosting its NAV, with the community noting its low float and potential for a significant upward move. Traders are actively discussing key breakout levels and comparing it to other low-float runners, while also considering the company's liquidation plan. The stock's small float has traders watching closely for a potential squeeze.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amidst mixed sentiment, with some community members expressing frustration over its price performance and questioning its utility, while others highlight its role as a foundational infrastructure for Web3 and the potential of its Neura platform. The debate centers on whether ANKR's underlying technology will translate to tangible returns for investors, or if it will remain an unappreciated component of the crypto ecosystem. Some are excited about the Neura L1 blockchain and its potential to reward developers.

WorldFinancial

WorldFinancial ($WLFI.X) is trending as traders discuss its potential, integrations, and real-world asset tokenization use cases. Community members are weighing bullish sentiments against concerns around market capitalization and involvement of controversial figures, as well as the token's recent volatility. Some traders believe the token is poised for a significant upward move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mineralys Therapeutics Inc. (195% increase in followers)Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other conditions linked to dysregulated aldosterone.Its lead candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed for cardiorenal conditions.Last month, Mineralys reported positive topline results from its Phase 3 Launch-HTN and Phase 2 Advance-HTN trials evaluating lorundrostat for uncontrolled and resistant hypertension. Both studies met their primary efficacy endpoints with statistical significance.&nbsp;In February, Mineralys reported a smaller-than-expected quarterly loss and disclosed that cash, cash equivalents, and investments stood at $198.2 million as of Dec. 31, 2024, which it expects to support clinical studies and corporate operations through the first quarter of 2026.The stock has gained over 28% year-to-date, with short interest at 4.5%, according to Koyfin.Sana Biotechnology Inc. (177% increase in followers)Sana focuses on developing engineered cell therapies to repair or replace damaged or missing cells, as well as control and modify genes.This year, the company has attracted significant investor interest following a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes. In January, it demonstrated that its hypoimmune edits enabled islet cell transplants to survive without immunosuppression, a result that drew praise from analysts.Last month, Citizens JMP upgraded Sana's stock, citing the validation of its Hypoimmune platform in type 1 diabetes, upcoming SC291 data in autoimmune diseases expected in 2025, and a strong cash position of $152.5 million. The firm considers Sana undervalued.Jefferies notes that Sana has three assets in development across different disease areas and projects peak adjusted revenues of $2.8 billion.Sana's stock is up just over 3% year-to-date, with short interest at 17.7%, according to Koyfin.Aeon Biopharma Inc. (132% increase in followers)This is a clinical-stage biopharmaceutical company developing ABP-450, a botulinum toxin complex for treating neurological conditions. Evolus markets the same botulinum toxin complex cosmetically under the name Jeuveau.ABP-450 is already approved as a biosimilar in Mexico and India. Aeon holds exclusive development and distribution rights for therapeutic indications in the U.S., Canada, the EU, the U.K., and select international markets.The stock gained attention this year following a 1-for-72 reverse stock split in March to maintain NYSE American's minimum share price requirement.Last month, Aeon announced that CEO Marc Forth would step down on April 4 to pursue another opportunity, with Chairman Jost Fischer stepping in as interim CEO.Aeon's stock has plunged over 98% year-to-date, with short interest last at 1.7%, according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

Equity

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

The biotech sector remains a hotbed for retail investor interest, with over 3.4 million users following these stocks on Stocktwits. Last week, the below three companies saw the highest increases in retail following:Kairos Pharma Ltd. (+83%)Kairos Pharma, a clinical-stage biopharmaceutical company focused on cancer therapeutics, saw the most spike in retail chatter.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.Retail interest soared last week after Kairos broke key resistance levels and secured crucial investments.&nbsp;The stock surged nearly 120% last Monday following positive comments from CEO John Yu at an investor healthcare summit.&nbsp;Additionally, the company completed a $3.5 million PIPE transaction, which the CEO said would ensure the continued progress of its clinical trials and asset development.&nbsp;Despite these gains, Kairos has lost 21% of its value since its NYSE debut in September.OS Therapies Inc. (+39%)Shares of OS Therapies jumped after the company reported positive clinical trial data for its OST-HER2 candidate, which targets a rare bone cancer that spreads to the lungs.&nbsp;Following the announcement, Maxim analyst Jason McCarthy raised the firm’s price target to $15 from $8, maintaining a ‘Buy’ rating.&nbsp;The data has positioned OS Therapies to meet with the FDA by the end of the first quarter of 2025 to discuss the possibility of filing for accelerated approval.The company is focused on oncology treatments, with OST-HER2 being its lead immunotherapy asset. It leverages listeria bacteria’s immune-stimulatory effects to target the HER2 protein in cancer cells.AEON Biopharma Inc. (+19%)AEON Biopharma is a company developing the proprietary botulinum toxin complex ABP-450, a biosimilar to Evolus’ Jeuveau, approved for cosmetic use, but AEON is developing it for medical indications.&nbsp;The company’s manufacturing partner, Daewoong, produces ABP-450 in FDA-approved facilities under current Good Manufacturing Practices (cGMP).Although there were no specific catalysts driving the recent spike, it appears that retail investors were buying the dip after the company priced a public offering to raise $20 million earlier this month, which had caused the stock to slide.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first...

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine...

AEON Biopharma Announces Redemption of Public Warrants

IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) ( AEON or the Company ), a clinical-stage biopharmaceutical company focused on developing a...

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine An interim analysis from the ongoing...

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4 weeks; durability of effect was demonstrated 12...

AEON Biopharma, Inc. is a biopharmaceutical company, which engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

Current Price	$0.7631
Prev Close	$0.7677
Open	$0.77
Dividend Yield	0.00%
50-Day Moving Average	$0.7681
Beta	0.45
Avg. Volume	88,076.33
PE Ratio	-0.13

52-Week High	$115.57
52-Week Low	$0.375
Market Capitalization	$8.89M
EPS (Annual)	$72.93
Price to Book	-0.56
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

AEON
AEON Biopharma Inc. - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Latest AEON News

AEON AEON Biopharma Inc. - Ordinary Shares - Class A